Treatment
Atezolizumab + Bevacizumab
4
Conditions
77
Trials
17K
Participants
40%
Average Safety
Condition Evidence
Liver cancer due to alcohol use
10 trials · 2,000 participants
65% effectiveness · 50% safety
Liver cancer due to hepatitis B
7 trials · 1,500 participants
85% effectiveness · 30% safety
Liver cancer due to hepatitis C
50 trials · 10K participants
78% effectiveness · 45% safety
Liver cancer due to NASH
10 trials · 3,000 participants
88% effectiveness · 35% safety